Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

42.53USD
18 Jan 2019
Change (% chg)

$0.06 (+0.14%)
Prev Close
$42.47
Open
$42.62
Day's High
$42.70
Day's Low
$42.26
Volume
15,059,992
Avg. Vol
7,433,854
52-wk High
$46.46
52-wk Low
$33.20

Select another date:

Wed, Jan 9 2019

Photo

Pfizer to shut two manufacturing plants in India

U.S. drugmaker Pfizer Inc said on Wednesday it was shutting down two manufacturing plants in India that make generic injectables like penicillin in response to falling demand.

UPDATE 1-Pfizer to shut two manufacturing plants in India

Jan 9 U.S. drugmaker Pfizer Inc said on Wednesday it was shutting down two manufacturing plants in India that make generic injectables like penicillin in response to falling demand.

CORRECTED-Pfizer to shut two manufacturing plants in India

Jan 9 U.S. drugmaker Pfizer Inc said on Wednesday it was shutting down two manufacturing plants in India that make generic injectables like penicillin as a response to falling demand.

REFILE-BRIEF-India's Pfizer Ltd Says News On Stopping Ops In Chennai, Aurangabad Units Unrelated To Co

* CLARIFIES ON NEWS ARTICLE ABOUT PFIZER TO STOP MANUFACTURING OPERATIONS IN CHENNAI, AURANGABAD UNITS

Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients.

UPDATE 2-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Dec 21 Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients.

CORRECTED-UPDATE 1-Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

Dec 21 Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug, Bavencio, to treat a form of ovarian cancer in previously untreated patients.

Merck KGaA-Pfizer to terminate late-stage ovarian cancer treatment study

Dec 21 Pfizer Inc and Merck KGaA said on Friday they were terminating a late-stage study for a drug to treat a form of ovarian cancer in previously untreated patients.

Novartis oncology boss Barrett makes quick exit

ZURICH Novartis is getting its third oncology chief in less than a year after Liz Barrett said on Thursday she was leaving the Swiss drugmaker to become chief executive of a U.S. biotech firm only 11 months after taking up the role.

Drugmaker GSK to split after striking Pfizer consumer health deal

LONDON GlaxoSmithKline plans to split into two businesses -- one for prescription drugs and vaccines, the other for over-the-counter products -- after forming a new joint venture with Pfizer's consumer health division. | Video

Select another date: